美FDA不同意IARC的阿斯巴甜可能致癌结论 美国当地时间2023年7月14日,美国食品药品监督管理局(FDA)官网发布其对阿斯巴甜外部安全审查的回应,称国际癌症研究机构(IARC)标记阿斯巴甜为“可能对人类致癌”,并不意味着阿斯巴甜实际上与癌症有关,FDA不同意IARC的结论。 FDA的科学家审查了2021年 IARC首次审查中包含的科学信息,发现了IARC所依赖的研究中存在重大缺陷。 FDA官网原文:(https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food)
[size=1.125]FDA Response to External Safety Reviews of Aspartame
[size=1.125]The FDA is aware of the International Agency for Research on Cancer (IARC) and Joint FAO/WHO Expert Committee on Food Additives (JECFA) conclusions about aspartame issued July 14, 2023. Aspartame being labeled by IARC as “possibly carcinogenic to humans” does not mean that aspartame is actually linked to cancer.
[size=1.125]The FDA disagrees with IARC’s conclusion that these studies support classifying aspartame as a possible carcinogen to humans. FDA scientists reviewed the scientific information included in IARC’s review in 2021 when it was first made available and identified significant shortcomings in the studies on which IARC relied. We note that JECFA did not raise safety concerns for aspartame under the current levels of use and did not change the Acceptable Daily Intake (ADI).
[size=1.125]Aspartame is one of the most studied food additives in the human food supply. FDA scientists do not have safety concerns when aspartame is used under the approved conditions. The sweetener is approved in many countries. Regulatory and scientific authorities, such asHealth CanadaExternal Link Disclaimerand theEuropean Food Safety AuthorityExternal Link Disclaimerhave evaluated aspartame and also consider it safe at current permitted use levels.
[size=1.125]Some consumers may rely on products with aspartame and other sweeteners to help reduce their sugar consumption. We recognize that navigating different information from health organizations is challenging. We will continue to provide reliable, science-based information on aspartame and other sweeteners on the FDA’s web site to help consumers make informed choices.
|